Investigating empagliflozin for treating autosomal dominant polycystic kidney disease
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
This study is looking at whether empagliflozin, a medication that helps with kidney health, can be a safe and effective treatment for people with autosomal dominant polycystic kidney disease (ADPKD), offering a new option besides the current treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10896266 on NIH RePORTER |
What this research studies
This research explores the use of empagliflozin, a sodium-glucose cotransporter-2 inhibitor, as a potential treatment for patients with autosomal dominant polycystic kidney disease (ADPKD). The study aims to assess the feasibility and safety of this medication, which has shown promise in other kidney diseases but has not been tested in ADPKD patients. By focusing on both kidney function and cardiovascular health, the research seeks to provide a well-tolerated alternative to the currently approved treatment, tolvaptan. Patients will be monitored for their response to the medication and any side effects experienced during the trial.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with autosomal dominant polycystic kidney disease.
Not a fit: Patients with other forms of kidney disease or those who do not have ADPKD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new, effective treatment option for slowing the progression of ADPKD and improving cardiovascular health.
How similar studies have performed: While SGLT2 inhibitors have shown success in other kidney conditions, this specific application in ADPKD is novel and has not been extensively tested.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Chonchol, Michel Benjamin — University of Colorado Denver
- Study coordinator: Chonchol, Michel Benjamin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.